MedTrace Logo

Efficacy and Safety Evaluation of Octreotide in the Treatment of Congenital Hyperinsulinemia

NCT05171751 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2021-12-29

No results posted yet for this study

Summary

To analyze and evaluate the efficacy and safety of octreotide subcutaneous injection in the treatment of diazazine-ineffective congenital hyperinsulinemia (CHI) in children.

Conditions

  • Congenital Hyperinsulinaemic Hypoglycaemia
  • Octreotide Adverse Reaction

Interventions

DRUG

Octreotide Injection

Octreotide subcutaneous injection for congenital hyperinsulinemia with ineffective diazine

Sponsors & Collaborators

  • Beijing Children's Hospital

    lead OTHER

Principal Investigators

  • bingyan cao, doctor · doctor of Beijing children's hospital

Eligibility

Min Age
1 Month
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-01
Primary Completion
2021-12-18
Completion
2021-12-18

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05171751 on ClinicalTrials.gov